IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R...
June 24 2014 - 8:45AM
Marketwired
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R))
Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R)
Radiation Therapy Balloon Catheter System
Liquid Cesium-131 Provides a Very Homogenous Dose of Radiation
Required in the Treatment of Recurrent Brain Cancers
RICHLAND, WA--(Marketwired - Jun 24, 2014) - IsoRay, Inc.
(NYSEMKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications, today
announced another milestone -- the treatment of a brain tumor that
had metastasized from esophageal cancer utilizing IsoRay's liquid
Cesium-131 (Cesitrex®) which recently was FDA cleared for internal
radiation therapy.
Dr. Randy Sorum, radiation oncologist and Dr. Ryan Halpin,
neurosurgeon at Capital Medical Center successfully completed the
world's first GliaSite® Radiation Therapy System (RTS) implant
utilizing liquid Cesium-131 (Cesitrex®). Dr. Sorum said "The
patient was a 72 year old male who was diagnosed with recurrent
brain cancer that had metastasized from esophageal
cancer. Earlier attempts to control this cancer including
surgery, external brain radiation and stereotactic radiosurgery had
failed and the metastasis returned."
Due to the need for irradiating the newly resected surgical bed,
Dr. Sorum decided to utilize GliaSite® RTS, a balloon catheter
system that delivers a high dose of radiation to the surgical bed,
minimizing radiation to uninvolved healthy brain tissue. Dr. Sorum
stated, "The unique benefit of GliaSite® is its capability to
deliver radiation directly to the high risk areas for recurrence,
unlike additional external beam radiation which likely would have
damaging effects to healthy brain tissue. GliaSite® RTS in
combination with Cesitrex® offers the additional benefit of
improved quality of life for the patient. To date the majority of
my patients treated with liquid I-125 (Iotrex®) and GliaSite® RTS
have exceeded my personal survival expectations and those reported
in published results. Most important, the patient receiving
Cesitrex® did great through the entire treatment process with no
post-operative side effects to date."
IsoRay CEO Dwight Babcock said, "This marks a milestone in
launching IsoRay's newest product into the US marketplace,
supporting management's goal to increase revenues and shareholder
value while improving the quality of life for the patient. Our hope
is to promote awareness that our product line, including both
Cesium-131 brachytherapy seeds and GliaSite® RTS utilizing liquid
Cesium-131 isotope (Cesitrex®), can take on difficult cancers
throughout the body. We are advancing our ultimate domestic
and international goal of making Cesium-131 a standard of care for
the treatment of multiple cancers and GliaSite® RTS a standard of
care for the treatment of brain cancer. We are extremely
pleased with the exceptional results a growing number of thought
leaders and major medical centers are experiencing throughout the
U.S. and internationally using Cesium-131. We believe Cesium-131's
ability to fight cancer and improve the quality of life for the
men, women, and children who are battling these devastating cancers
distinguishes it from other treatment options."
IsoRay is the exclusive manufacturer of Cesium-131. The
pioneering brachytherapy is one of the most significant advances in
internal radiation therapy in 20 years. Cesium-131 allows for
the precise treatment of many different cancers because of its
unrivaled blend of high energy and its 9.7 day half-life (its
unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and
holds a CE mark for international sales in seed form for the
treatment of brain cancer, prostate cancer, lung cancer, ocular
melanoma cancer, colorectal cancer, gynecologic cancer, head and
neck cancer and other cancers throughout the body. The treatment
can be deployed using several delivery methods including single
seed applicators, implantable strands and seed sutured mesh, and
several implantable devices including the GliaSite® radiation
therapy system, the world's only liquid radiation balloon catheter
device used in the treatment of brain cancer.
About IsoRay IsoRay, Inc., through its subsidiary, IsoRay
Medical, Inc., is the sole producer of Cesium-131 brachytherapy
seeds, which are expanding brachytherapy options throughout the
body. Learn more about this innovative Richland, Washington
company and explore the many benefits and uses of Cesium-131 by
visiting www.isoray.com.
Join us on Facebook/Isoray. Follow us on Twitter
@Isoray.
Safe Harbor Statement Statements in this news release about
IsoRay's future expectations, including: the advantages of our
products and their various delivery formats and systems, whether
adoption of our products will continue to increase, whether IsoRay
will be able to continue to expand its base beyond prostate cancer,
whether treated cancers will reoccur, whether future studies of
treatment of various cancers using our products will have favorable
results, whether sales of our products will continue at historic
levels or increase, whether the use of our products will increase
or continue, whether future clinical results achieved with
treatment using Cesium-131 in the GliaSite® radiation therapy
system will be favorable, whether awareness of our products in the
medical community will continue or increase, and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement
is included for the express purpose of availing IsoRay, Inc. of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as physician acceptance, training
and use of our products, our ability to successfully manufacture,
market and sell our products, our ability to manufacture our
products in sufficient quantities to meet demand within required
delivery time periods while meeting our quality control standards,
our ability to enforce our intellectual property rights, whether
ongoing patient results with our products are favorable and in line
with the conclusions of clinical studies and initial patient
results, patient results achieved when our products are used for
the treatment of cancers and malignant diseases beyond prostate,
whether additional studies are released and support the conclusions
of past studies, whether we, our distributors and our customers
will successfully obtain and maintain all required regulatory
approvals and licenses to market, sell and use our products in its
various forms both in the U.S. and internationally, successful
completion of future research and development activities, the
success of our sales and marketing efforts, changes in
reimbursement rates, changes in laws and regulations applicable to
our products, continued compliance with ISO standards as audited by
BSI, and other risks detailed from time to time in IsoRay's reports
filed with the SEC.
Contact: IsoRay Medical (509) 375-1202 Info@Isoray.com Worldwide
Financial (954) 360-9998 info@wwfinancial.com
IsoRay (AMEX:ISR)
Historical Stock Chart
From Mar 2024 to Apr 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2023 to Apr 2024